This study has two parts: dose escalation and dose expansion.
The primary objectives are:
- For Dose Escalation, to assess the safety and tolerability of DS-1205c when combined
with osimertinib in the study population and to determine the recommended dose for
expansion of DS-1205c when combined with osimertinib in the study population
- For Dose Expansion, to assess the safety and tolerability of DS-1205c when combined with
osimertinib in the study population
In Dose Escalation, after a 7-day run in period (Cycle 0), there will be 21-day cycles (Cycle
1 onward). In Dose Expansion, there will be 21-day cycles.
The number of treatment cycles is not fixed in this study. Participants will continue study
treatment for 36 months unless they decide not to (withdraw consent), their disease gets
worse [progressive disease (PD)], or side effects become unacceptable (unacceptable
1. Has histologically or cytologically documented adenocarcinoma NSCLC.
2. Has locally advanced or metastatic NSCLC, not amenable to curative surgery or
3. Has acquired resistance to EGFR TKI according to the Jackman criteria (PMID:
1. Historical confirmation that the tumor harbors an EGFR mutation known to be
associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R,
2. Has experienced clinical benefit from an EGFR TKI, followed by systemic
progression (Response Evaluation Criteria in Solid Tumors [RECIST version 1.1] or
World Health Organization [WHO]) while on continuous treatment with an EGFR TKI.
4. Is currently receiving and able to discontinue erlotinib, gefinitib, or afatinib.
5. Has been receiving erlotinib, gefitinib, or afatinib for at least 6 weeks with
well-controlled related toxicities less than Grade 3 in severity at the time of
6. Has radiological documentation of disease progression while receiving continuous
treatment with erlotinib, gefitinib, or afatinib.
7. Has at least one measurable lesion per RECIST version 1.1.
8. Is willing to provide archival tumor tissue from a biopsy performed within 6 months of
progression during treatment with erlotinib, gefitinib, or afatinib OR has at least
one lesion, not previously irradiated, amenable to core biopsy and is willing to
undergo screening tumor biopsy.
9. Demonstrates absence of EGFR T790M.
10. Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, with no
deterioration over the previous 2 weeks.
1. Has any evidence of small cell histology, or combined small cell and non-small cell
histology, in original tumor biopsy or in screening biopsy performed since
2. Has previously documented evidence of ALK fusion, ROS1 fusion, BRAF V600E mutation,
RET rearrangement, HER2 mutation, MET amplification, or MET exon 14 skipping mutation.
No new testing for these genomic alterations is required for Screening.
3. Has received treatment with any of the following:
1. Any cytotoxic chemotherapy, immune checkpoint inhibitor therapy, investigational
agent or other anticancer drug(s) from a previous cancer treatment regimen or
clinical study (other than EGFR TKI), within 14 days of the first dose of study
2. Immune checkpoint inhibitor therapy within 30 days of first dose of study
3. Major surgery (excluding placement of vascular access) within 4 weeks of the
first dose of study treatment.
4. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field
of radiation within 4 weeks, or palliative radiation therapy within 2 weeks of
the first dose of study drug treatment.
4. Has history of other active malignancy within 3 years prior to enrollment, except:
1. Adequately treated non-melanoma skin cancer OR
2. Superficial bladder tumors (Ta, Tis, T1) OR
3. Curatively treated in situ disease
5. Has spinal cord compression or clinically active brain metastases, defined as
untreated and symptomatic, or requiring therapy with corticosteroids or
anticonvulsants to control associated symptoms. Subjects with clinically inactive
brain metastases may be included in the study. Subjects with treated brain metastases
that are no longer symptomatic and who require no treatment with corticosteroids or
anticonvulsants may be included in the study if they have recovered from the acute
toxic effect of radiotherapy. A minimum of 2 weeks must have elapsed between the end
of whole brain radiotherapy and study enrollment (1 week for stereotactic
6. Presence of retinal disease in the eye that is not due to neovascular age-related
macular degeneration (nAMD; eg, significant diabetic retinopathy, glaucomatous retinal
atrophy, retinal detachment).
7. Has history of myocardial infarction within the past 6 months.
8. Has symptomatic congestive heart failure (New York Heart Association [NYHA] Classes
II-IV), unstable angina, or cardiac arrhythmia requiring antiarrhythmic treatment.
9. Has left ventricular ejection fraction (LVEF) < 45% by either echocardiogram (ECHO) or
multigated acquisition (MUGA) scan.
10. Has any clinically important abnormalities in rhythm, conduction or morphology of
resting ECG, eg, complete left bundle branch block, third-degree heart block,
second-degree heart block, or PR interval > 250 milliseconds (ms).
11. Has a mean QTcF prolongation >470 ms for females and >450 ms for males in three
successive Screening measurements.
12. Unable or unwilling to discontinue concomitant use of drugs that are known to prolong
the QT interval.
13. Has any factors that increase the risk of QTc prolongation or risk of arrhythmic
events, such as congenital long QT. syndrome, family history of long QT syndrome or
unexplained sudden death under 40 years of age in first degree relatives.
14. Has any history of interstitial lung disease (pulmonary fibrosis or severe radiation
pneumonitis) or is suspected to have such disease by imaging during screening.